Prostate cancer incidence in France is significantly higher than the European average of 153.9 per 100,000 population, at a rate of 201 per 100,000.1 Prostate cancer is the most commonly diagnosed cancer in French males, accounting for 25% of all male cancers. 66% of cases are in men aged 65 and over.2
Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members
1 European Cancer Information System (ECIS). Estimates of cancer incidence and mortality in 2020. Accessible at https://ecis.jrc.ec.europa.eu/explorer.php?$0-0$1-All$2-All$4-1$3-34$6-0,85$5-2008,2008$7-7$CEstByCountry$X0_8-3$X0_19-AE27$X0_20-No$CEstBySexByCountry$X1_8-3$X1_19-AE27$X1_-1-1$CEstByIndiByCountry$X2_8-3$X2_19-AE27$X2_20-No$CEstRelative$X3_8-3$X3_9-AE27$X3_19-AE27$CEstByCountryTable$X4_19-AE27 (last accessed March 2022)
2 National Institute for Cancer. Prostate Cancer. Accessible at https://www.e-cancer.fr/Professionnels-de-sante/Les-chiffres-du-cancer-en-France/Epidemiologie-des-cancers/Les-cancers-les-plus-frequents/Cancer-de-la-prostate (last accessed March 2022)
Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members
European Cancer Information System (ECIS). Estimates of cancer incidence and mortality in 2020. Accessible at https://ecis.jrc.ec.europa.eu/explorer.php?$0-0$1-All$2-All$4-1$3-34$6-0,85$5-2008,2008$7-8$CEstByCountry$X0_8-3$X0_19-AE27$X0_20-No$CEstBySexByCountry$X1_8-3$X1_19-AE27$X1_-1-1$CEstByIndiByCountry$X2_8-3$X2_19-AE27$X2_20-No$CEstRelative$X3_8-3$X3_9-AE27$X3_19-AE27$CEstByCountryTable$X4_19-AE27 (last accessed March 2022)
Mortality rates for prostate cancer in France are slightly below the EU27 average of 32.1 per 100,000 population, at a rate of 27.6 per 100,000.1 There are around 9,000 deaths from prostate cancer in France every year.2 However, according to a 2019 report, the gross mortality rate in France was 27.3 per 100,000 population in 2015.3
Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members
1 European Cancer Information System (ECIS). Estimates of cancer incidence and mortality in 2020. Accessible at https://ecis.jrc.ec.europa.eu/explorer.php?$0-0$1-All$2-All$4-1$3-34$6-0,85$5-2008,2008$7-8$CEstByCountry$X0_8-3$X0_19-AE27$X0_20-No$CEstBySexByCountry$X1_8-3$X1_19-AE27$X1_-1-1$CEstByIndiByCountry$X2_8-3$X2_19-AE27$X2_20-No$CEstRelative$X3_8-3$X3_9-AE27$X3_19-AE27$CEstByCountryTable$X4_19-AE27 (last accessed March 2022)
2 WHO. International Agency for Research on Cancer. France Factsheet. Accessible at https://gco.iarc.fr/today/data/factsheets/populations/250-france-fact-sheets.pdf (last accessed March 2022)
3 Defossez, G, et al. Estimations nationales de l’incidence et de la mortalité par cancer en France métropolitaine entre 1990 et 2018. June 2019. Accessible at https://www.e-cancer.fr/content/download/266013/3752411/file/
Estimations_incidence_mortalite_cancer_France_1990_2018_tumeurs_solides_mel_20190702.pdf (last accessed March 2022)
Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members
European Cancer Information System (ECIS). Estimates of cancer incidence and mortality in 2020. Accessible at https://ecis.jrc.ec.europa.eu/explorer.php?$0-0$1-All$2-All$4-1$3-34$6-0,85$5-2008,2008$7-8$CEstByCountry$X0_8-3$X0_19-AE27$X0_20-No$CEstBySexByCountry$X1_8-3$X1_19-AE27$X1_-1-1$CEstByIndiByCountry$X2_8-3$X2_19-AE27$X2_20-No$CEstRelative$X3_8-3$X3_9-AE27$X3_19-AE27$CEstByCountryTable$X4_19-AE27 (last accessed March 2022)
From 2010-2014, the 5-year net survival rate for prostate cancer patients in France was 93.1%,1 putting France in the top 5 EU countries with the highest survival rates behind Finland, Belgium, Lithuania and Cyprus.
Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members
1 Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)
Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members
Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)
A new ten-year Cancer Control Strategy (2021-2030) for France has come into effect. Input to the Strategy has been received by key stakeholders since 2018, including patients, patient associations, research organisations, hospital federations, health insurance providers and healthcare professionals.
Analysis of the political profile of prostate cancer in France shows that it does not receive the attention that would be expected given the scale and impact of the disease. Between January 2015 and 2020, prostate cancer was significantly less featured in political activity than other comparable cancers. While 95 parliamentary questions were asked on breast cancer, just 63 were asked on prostate cancer. In addition, there were 20 ministerial statements on breast cancer in the same period, compared to only 3 on prostate cancer.
The French Society of Urology’s Cancerology Committee has produced prostate cancer guidelines for 2020-2022. The recommended care pathway, includes patient access to*:
Legend:
Recommendation included
Recommendation not included
Access to Specialists
The number of urologists per citizen in France is relatively low, with 44,444 citizens to every 1 urologist.1 This puts France in the bottom 6 EU countries with the least number of urologists per citizen, alongside the Netherlands,2 Finland,3 Denmark,4 the UK5 and Ireland.6
Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members
1 European Society of Residents in Urology (ESRU). France. March 2018. Accessible at https://esru.eu/?q=france (last accessed March 2022)
2 European Society of Residents in Urology (ESRU). Netherlands. March 2018. Accessible at https://esru.eu/?q=netherlands (last accessed March 2022)
3 European Society of Residents in Urology (ESRU). Finland. March 2018. Accessible at https://esru.eu/?q=finland (last accessed March 2022)
4 European Society of Residents in Urology (ESRU). Denmark. March 2018. Accessible at https://esru.eu/?q=denmark (last accessed March 2022)
5 Palmer, M and Taylor, C. British Association of Urological Surgeons and The Specialist Advisory Committee in Urology: Workforce Report. 2018. Accessible at https://www.baus.org.uk/_userfiles/pages/files/publications/Workforce_Report_Sep%202018%20ver%201.1.pdf (last accessed March 2022)
6 European Society of Residents in Urology (ESRU). Ireland. March 2018. Accessible at https://esru.eu/?q=ireland (last accessed March 2022)
Cost of cancer
In 2018, the direct cost of cancer in France was €278 per person,1 significantly higher than the European average of €154 per person.2 This is behind Germany, which spends €308 per person.1 Whilst a number of factors contribute to improved outcomes for those affected by prostate cancer, studies have shown that those countries that invest more in cancer care tend to achieve better outcomes for patients.3
Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members
1 Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)
2 Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022) – average calculated from data included for individual countries.
3 Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7.
Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members
1 Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)
Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members
*Different data sources were used for Belgium, Hungary, Italy, Romania and the UK, which may use data from different years. See references below. No data was found for Cyprus, Luxembourg, Malta and Slovakia.
European Society of Residents in Urology (ESRU). Countries. March 2018. Accessible at https://esru.eu/?q=countries (last accessed March 2022)
Federal Public Service of Public Health, Safety of the Food Chain and the Environment. HWF STATAN 2019 (detailed statistics). 2019. Accessible at https://organesdeconcertation.sante.belgique.be/fr/documents/hwf-statan-2019-statistiques-detaillees (last accessed March 2022)
Boszormenyi-Nagy, G. Report on urological inpatient care based on 2018 data. Urologia Hungarica. Accessible at http://urologiahungarica.hu/index.php/2020/05/12/beszamolo-az-urologiai-fekvobeteg-ellatasrol-a-2018-as-adatok-alapjan/ (last accessed March 2022)
I.Stat. Personale sanitario. Accessible at http://dati.istat.it/Index.aspx?DataSetCode=DCIS_PERS_SANIT (last accessed March 2022)
Institutul National De Statistica. Activitatea Unitatilor Sanitare in Anul 2019. 2020. Accessible at https://insse.ro/cms/sites/default/files/field/publicatii/activitatea_unitatilor_sanitare_anul_2019.pdf (last accessed March 2022)
United Nations, Population Division, Department of Economic and Social Affairs. World Population Prospects 2019. Accessible at https://population.un.org/wpp/Download/Files/1_Indicators%20(Standard)/EXCEL_FILES/1_Population/
WPP2019_POP_F01_1_TOTAL_POPULATION_BOTH_SEXES.xlsx (last accessed March 2022)
British Association of Urological Surgeons and The Specialist Advisory Committee in Urology. Workforce Report. 2018. Accessible at https://www.baus.org.uk/_userfiles/pages/files/publications/
Workforce_Report_Sep%202018%20ver%201.1.pdf (last accessed March 2022)
Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members
Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)
Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members
Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)
Prostate cancer organisations in France include:
ANAMACAP
https://www.anamacap.fr/
CERHOM
http://cerhom.fr/
Reference Number: ONC_2021_0131_BE
Date of preparation: January 2022
